Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH(2) Through Ultrasound to Enhance the Antitumor Efficacy and Attenuate the Toxicity for Treatment of Malignant Glioma

BACKGROUND: Glioma is the most common and malignant primary brain tumour in adults and has a dismal prognosis. Temozolomide (TMZ) is the only clinical first-line chemotherapy drug for malignant glioma up to present. Due to poor aqueous solubility and toxic effects, TMZ is still inefficient and limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Zhiping, Li, Chunlin, Gu, Jinmao, Qian, Jun, Zhu, Junle, Wang, Jiaqi, Li, Yinwen, Jiang, Jiahao, Chen, Huairui, Luo, Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517532/
https://www.ncbi.nlm.nih.gov/pubmed/34675514
http://dx.doi.org/10.2147/IJN.S330187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517532/
https://www.ncbi.nlm.nih.gov/pubmed/34675514
http://dx.doi.org/10.2147/IJN.S330187

Ejemplares similares